Overview

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Pfizer

Treatments:

Apixaban
Pharmaceutical Solutions